03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseNextNext post:AB Science announces a slight delay in the publication of its 2023 annual financial reportRelated PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
